ROMVIMZA: Uses, Dosage & Side Effects
A selective oral CSF1R kinase inhibitor used to treat adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgery would cause worsening functional limitation or severe morbidity
ROMVIMZA (vimseltinib) is an oral, switch-control selective inhibitor of the colony-stimulating factor 1 receptor (CSF1R) used to treat adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgery would cause worsening functional limitation or severe morbidity. TGCT is a rare, locally aggressive but generally non-malignant tumour of the synovial lining of joints, bursae and tendon sheaths, driven by abnormal CSF1 signalling that recruits and expands inflammatory macrophages. By blocking the CSF1R kinase, ROMVIMZA shrinks tumours, reduces pain, restores range of motion and improves quality of life. It is taken as 14 mg hard capsules twice weekly and was approved on the basis of the pivotal phase 3 MOTION trial.
Quick Facts: ROMVIMZA
Key Takeaways
- ROMVIMZA (vimseltinib) is a precision oral therapy that selectively blocks the CSF1R kinase, the central driver of tenosynovial giant cell tumor (TGCT). It is not a conventional cytotoxic chemotherapy.
- The pivotal phase 3 MOTION trial demonstrated a 40% objective response rate at week 25 versus 0% with placebo, with concurrent improvements in pain, joint stiffness and physical function.
- The standard regimen is 30 mg taken twice weekly, with at least 72 hours between doses; capsules can be taken with or without food, but acid-reducing medicines (e.g., proton pump inhibitors) should be avoided.
- The most common adverse effects are periorbital and peripheral oedema, fatigue, headache, rash and laboratory abnormalities (elevated AST/ALT, cholesterol, creatine kinase) – serious hepatotoxicity is uncommon but requires routine liver function monitoring.
- Both women and men of reproductive potential must use highly effective contraception during therapy and for at least one month after the last dose. ROMVIMZA may reduce the effectiveness of hormonal contraceptives, so a non-hormonal barrier method is recommended.
What Is ROMVIMZA and What Is It Used For?
ROMVIMZA contains the active substance vimseltinib, a small-molecule, switch-control inhibitor of the colony-stimulating factor 1 receptor (CSF1R) tyrosine kinase. Tyrosine kinases are intracellular signalling enzymes that turn growth, survival and inflammation signals on and off in cells. Vimseltinib was specifically engineered to lock CSF1R in an inactive conformation, providing both high selectivity for CSF1R and a long enough plasma half-life to enable convenient twice-weekly oral dosing. The compound was originally developed by Deciphera Pharmaceuticals under the laboratory code DCC-3014, and its marketing rights are now held within the Ono Pharmaceutical group.
ROMVIMZA is approved for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection would either result in worsening functional limitation or severe morbidity. TGCT – previously known as pigmented villonodular synovitis (PVNS) when affecting the joint and as giant cell tumour of the tendon sheath when affecting tendons – is a rare, locally aggressive but generally non-malignant tumour of the synovium that lines joints, bursae and tendon sheaths. It most often involves the knee, hip, ankle, wrist and shoulder, but can occur at any synovial site. Although TGCT does not metastasise, the diffuse subtype can erode bone, destroy cartilage and severely impair joint function, sometimes leading to repeated surgeries or eventual joint replacement.
The molecular biology of TGCT is unique among solid tumours. In the great majority of cases, a chromosomal translocation in a small fraction of synovial cells places the gene encoding the colony-stimulating factor 1 (CSF1) under the control of an unrelated, highly active promoter. The result is large quantities of CSF1 being secreted into the joint space. CSF1 is the natural ligand for CSF1R, a receptor expressed on the surface of monocytes and macrophages. The high local CSF1 levels recruit CSF1R-bearing macrophages from the bloodstream, which proliferate inside the synovium and produce the bulk of the tumour mass. This is why TGCT is sometimes described as a "landscape effect" tumour: the truly transformed cells are few, but they orchestrate an exuberant macrophage proliferation that causes the clinical disease.
By inhibiting CSF1R, ROMVIMZA interrupts this signalling axis. Macrophages already present in the tumour stop proliferating and undergo apoptosis, and new macrophages are no longer recruited from the circulation. Over weeks and months, the tumour mass shrinks, joint inflammation subsides, range of motion improves and pain decreases. Because vimseltinib spares other related kinases, including KIT, FLT3 and PDGFR, the side-effect profile differs from older, less selective CSF1R inhibitors and chemotherapy.
ROMVIMZA was approved by the U.S. Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) in 2025 on the basis of the pivotal MOTION phase 3 trial (NCT05059262). MOTION was a double-blind, placebo-controlled study in adults with symptomatic TGCT for whom surgery was considered to cause unacceptable morbidity. At week 25, vimseltinib produced an objective response rate of 40%, compared with 0% in the placebo arm, by independent central radiology review using RECIST v1.1 criteria. Patients also reported clinically meaningful improvements in pain (worst pain numeric rating scale), stiffness, range of motion and physical function. ROMVIMZA is intended for chronic, ongoing use as long as the patient continues to derive benefit and tolerates the medication.
ROMVIMZA is not a traditional cytotoxic chemotherapy. Instead of indiscriminately killing dividing cells, it precisely blocks one specific signalling protein (CSF1R) responsible for the abnormal macrophage activity that drives TGCT. This is why ROMVIMZA does not typically cause hair loss, severe bone marrow suppression or mucositis, but does have its own characteristic side-effect profile dominated by oedema and laboratory changes.
What Should You Know Before Taking ROMVIMZA?
Before starting ROMVIMZA, your doctor will perform a careful clinical and laboratory assessment to confirm the diagnosis of TGCT, evaluate the severity of symptoms, and check that your liver and overall health are suitable for treatment. Because TGCT is a chronic condition and ROMVIMZA is intended for long-term use, the decision to start therapy is usually made jointly by you and a multidisciplinary team that may include an oncologist, an orthopaedic oncology surgeon, a pathologist and a musculoskeletal radiologist.
Contraindications
There are situations in which ROMVIMZA must not be used. The single absolute contraindication is hypersensitivity:
- Hypersensitivity: Do not take ROMVIMZA if you have ever had a known allergic reaction to vimseltinib or to any of the inactive ingredients in the capsule. Allergic reactions to medicines can range from mild rash to severe anaphylaxis with breathing difficulty and circulatory collapse.
In addition, ROMVIMZA has not been studied in patients with severe hepatic impairment (Child-Pugh class C) and is generally not recommended for this population unless an experienced specialist decides that the potential benefit outweighs the risk.
Warnings and Precautions
ROMVIMZA can cause increases in liver enzymes (AST, ALT), alkaline phosphatase and bilirubin. These changes are usually asymptomatic and reversible after dose reduction or temporary interruption, but in rare cases they can progress to clinically significant liver injury. Liver function tests should be performed before starting treatment, every two weeks for the first two months, and then at least monthly. Contact your doctor immediately if you develop yellowing of the skin or eyes (jaundice), unusual tiredness, dark urine, pale stools, severe nausea or pain in the upper right abdomen.
Before and during treatment with ROMVIMZA, inform your doctor if any of the following apply to you:
- Liver disease: A history of hepatitis, fatty liver, alcohol-related liver injury, autoimmune hepatitis or any condition that has previously caused abnormal liver tests increases your risk of hepatotoxicity. Your doctor may decide to monitor liver function more frequently.
- Periorbital and peripheral oedema: Swelling around the eyes (periorbital oedema) and in the hands, ankles and feet (peripheral oedema) is the most characteristic adverse effect of CSF1R inhibition. It typically appears within the first weeks of treatment and is usually mild to moderate, but it can be cosmetically distressing or, rarely, severe enough to require dose adjustment. Tell your doctor about new or worsening swelling, especially if it is associated with shortness of breath, weight gain, or rapid changes in vision.
- Cardiovascular and metabolic risk factors: ROMVIMZA can cause increases in total cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides. If you already have high cholesterol, diabetes or established cardiovascular disease, your doctor may add or adjust lipid-lowering therapy and check lipid levels periodically.
- Skin reactions: Rash, itching, dry skin and changes in skin colour have been reported. Most reactions are mild and respond to topical moisturisers or short courses of topical corticosteroids, but severe reactions can occur. Report any extensive, painful or blistering rash promptly.
- Surgery and dental procedures: Tell your surgical or dental team that you are taking ROMVIMZA before any planned procedure. Although vimseltinib does not directly affect platelet count or coagulation, it may delay wound healing in some patients.
- Vaccinations: While ROMVIMZA is not classed as a strongly immunosuppressive drug, it does affect macrophage function. Talk to your doctor before receiving live attenuated vaccines (e.g., MMR, varicella, yellow fever, BCG) during therapy.
- Older adults: Patients aged 65 years and older may be more sensitive to oedema, fatigue and laboratory abnormalities. Closer clinical follow-up may be appropriate.
Your doctor will discuss the balance between the expected benefits of ROMVIMZA in your specific situation and these potential risks before treatment is initiated.
Recommended Laboratory Monitoring
Routine laboratory monitoring is an integral part of safe ROMVIMZA therapy. The following tests are typically performed:
- Liver function: AST, ALT, alkaline phosphatase, total bilirubin and gamma-glutamyl transferase (GGT) at baseline, every two weeks for the first eight weeks, then monthly during the first six months, and at least every three months thereafter.
- Lipid profile: Total cholesterol, LDL, HDL and triglycerides at baseline and periodically during treatment.
- Creatine kinase (CK): Periodic measurement, particularly if you experience new muscle pain, weakness or dark urine.
- Complete blood count and renal function: Baseline and periodic, mainly to monitor general health and detect intercurrent illness.
Pregnancy, Contraception and Breastfeeding
Based on its mechanism of action and animal reproductive toxicity studies, ROMVIMZA can cause harm to an unborn child when taken during pregnancy. Embryo-foetal lethality, structural malformations and reduced foetal weight have been observed in animals at exposures comparable to or below the human therapeutic dose. ROMVIMZA must not be used during pregnancy unless your doctor judges that the benefit outweighs the risk and that there is no acceptable alternative.
Women of reproductive potential should have a pregnancy test before starting ROMVIMZA and use highly effective contraception during treatment and for at least one month after the last dose. Vimseltinib may reduce the effectiveness of hormonal contraceptives such as combined oral contraceptive pills, progestogen-only pills, hormonal patches, vaginal rings and implants. For this reason, women using hormonal contraception should add a non-hormonal barrier method (e.g., condom plus spermicide), or switch to a non-hormonal method such as a copper intrauterine device (IUD).
Men with female partners of reproductive potential should also use effective contraception (e.g., condom) during treatment and for at least one month after the last dose, since the impact of vimseltinib on male fertility and sperm quality has not been fully characterised.
It is not known whether vimseltinib or its metabolites are excreted in human breast milk. Because of the potential for serious adverse reactions in a breastfed infant, breastfeeding is not recommended during treatment with ROMVIMZA and for at least one week after the last dose.
Driving and Operating Machinery
ROMVIMZA may cause fatigue, headache, dizziness or visual disturbance (related to periorbital oedema) in some patients. If you experience any of these effects, do not drive, cycle or operate heavy machinery until they have resolved. Most patients are able to continue normal daily activities, but you should monitor your own response carefully, especially during the first weeks of treatment and after any dose change.
Important Information About the Capsule Contents
ROMVIMZA hard capsules contain conventional pharmaceutical excipients (fillers, lubricants and capsule shell components). The exact list is provided in the package leaflet. The capsules contain only small amounts of sodium and lactose; if you have a hereditary problem of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption, ask your pharmacist before starting therapy.
How Does ROMVIMZA Interact with Other Drugs?
Vimseltinib is metabolised predominantly by the cytochrome P450 enzyme CYP3A4 in the liver, with minor contributions from other CYP enzymes. As a result, drugs that strongly inhibit or induce CYP3A4 can change the plasma concentration of vimseltinib in clinically meaningful ways. Vimseltinib is also a substrate of P-glycoprotein (P-gp), and absorption is influenced by gastric pH because of the pH-dependent solubility of the molecule. Always provide your doctor and pharmacist with a complete and updated list of every prescription medicine, over-the-counter product and herbal supplement you are taking before starting ROMVIMZA and again whenever a new medicine is added or stopped.
Major Interactions
| Interacting Drug or Class | Effect | Clinical Significance |
|---|---|---|
| Strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, voriconazole, ritonavir, clarithromycin, cobicistat) | Marked increase in vimseltinib plasma concentration; greater risk of oedema, hepatotoxicity and laboratory abnormalities | Avoid co-administration when possible. If unavoidable, dose reduction of ROMVIMZA may be required – follow specialist advice |
| Strong CYP3A4 inducers (e.g., rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital, St John’s wort) | Substantial decrease in vimseltinib exposure; potential loss of efficacy | Avoid co-administration. Choose alternative non-inducing therapies whenever possible |
| Acid-reducing agents (proton pump inhibitors such as omeprazole, esomeprazole; H2 antagonists; antacids) | Increased gastric pH reduces vimseltinib solubility and absorption, lowering plasma exposure | PPIs should be avoided. If short-term acid suppression is needed, antacids can be used at least 2 hours before or after ROMVIMZA |
| Hormonal contraceptives (combined oral pills, progestogen-only pills, patches, vaginal rings, implants) | Possible reduction in contraceptive hormone levels and contraceptive effectiveness | Add a non-hormonal barrier method or use a copper IUD during treatment and for at least 1 month after the last dose |
Other Interactions to Consider
| Interacting Drug or Class | Effect | Clinical Significance |
|---|---|---|
| Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole, diltiazem, verapamil, grapefruit juice) | Modest increase in vimseltinib levels | Use with caution; monitor for increased side effects, especially oedema and liver enzyme elevation |
| Moderate CYP3A4 inducers (e.g., efavirenz, modafinil, bosentan) | Modest decrease in vimseltinib levels | Monitor clinical response; consider alternative therapy if tumour control appears suboptimal |
| P-gp inhibitors and inducers | Possible alteration of vimseltinib absorption and tissue distribution | No formal dose adjustment recommended; review on a case-by-case basis |
| Hepatotoxic medications (e.g., high-dose paracetamol, methotrexate, isoniazid, certain statins, alcohol) | Additive risk of liver injury | Use with caution; intensify liver function monitoring |
| Drugs that prolong the QT interval | Additive risk of QT prolongation, although vimseltinib has a low intrinsic QT-prolonging potential | Consider baseline ECG and electrolyte monitoring in patients with cardiac risk factors |
Some interactions arise not from medicines but from foods, drinks and supplements. Grapefruit and grapefruit juice contain compounds that inhibit CYP3A4 and should be avoided during ROMVIMZA treatment. Alcohol is best limited because of the additional liver burden it places on a patient already taking a hepatically metabolised drug. Calcium supplements, iron and antacids can be taken several hours apart from ROMVIMZA to minimise absorption interactions.
What Is the Correct Dosage of ROMVIMZA?
ROMVIMZA is taken by mouth as a hard capsule. Dosing is based on a fixed regimen rather than on body weight or body surface area. Treatment should be initiated and monitored by a physician experienced in the management of TGCT, typically a medical oncologist, sarcoma specialist or orthopaedic oncologist. Always take ROMVIMZA exactly as your doctor has instructed and read the package leaflet supplied with your medicine.
Standard Dose for Adults
Adult Patients with Tenosynovial Giant Cell Tumor (TGCT)
Indication: Symptomatic TGCT for which surgery would cause worsening functional limitation or severe morbidity
Recommended dose: 30 mg orally twice weekly
Schedule: Two doses per week separated by at least 72 hours (for example, Monday and Thursday, or Tuesday and Friday). Choose the same two days each week to support consistent dosing.
Administration: Swallow capsules whole with a glass of water. Capsules may be taken with or without food. Do not chew, crush or open the capsules.
Duration: Continuous, ongoing therapy as long as the patient is benefiting and tolerating the medication. There is no fixed maximum duration.
The 30 mg dose is achieved using the available strengths of ROMVIMZA capsules according to the prescribing information in your country. Your pharmacist will dispense the correct combination of capsules and explain how many to take at each scheduled dose. If you are unsure about how many capsules to take, do not guess – contact your pharmacist or treatment team.
If You Miss or Vomit a Dose
If you miss a scheduled dose of ROMVIMZA, take it as soon as you remember on the same day. If you do not remember until the day of your next scheduled dose, skip the missed dose and take the next dose at your usual time. Never take a double dose to make up for a missed one. If you vomit shortly after taking a dose, do not take an extra capsule; simply continue with your normal schedule and tell your doctor at the next visit if vomiting is recurrent.
In Case of Overdose
If you take more ROMVIMZA than you should – either by mistake or intentionally – contact your doctor, hospital emergency department or local poisons information centre immediately. Bring the medication packaging with you so that healthcare professionals can identify the dose. There is no specific antidote to vimseltinib; management is supportive and may include observation, intravenous fluids, anti-emetics and close monitoring of liver function.
Dose Modifications for Side Effects
Your doctor may need to interrupt treatment, reduce the dose or, in rare cases, stop ROMVIMZA permanently because of side effects. Typical reasons for dose modification include:
- Hepatotoxicity: Significant elevation of AST or ALT (e.g., greater than 5 times the upper limit of normal), or any elevation of bilirubin associated with transaminase increases, generally requires temporary interruption until values recover. ROMVIMZA may then be resumed at a lower dose.
- Severe oedema: Disabling periorbital or peripheral oedema not controlled with conservative measures (elevation, compression, sodium restriction, short courses of diuretics) may require dose reduction.
- Severe rash or other intolerable skin reactions: Treatment may be paused until the reaction resolves; topical or systemic corticosteroids may be added at the discretion of the treating physician.
- Persistent metabolic abnormalities: Significant increases in cholesterol, triglycerides or creatine kinase that do not respond to lifestyle modifications and lipid-lowering therapy may prompt dose adjustment.
- Other Grade 3 or higher adverse events: Most other moderate to severe events are managed with dose interruption followed by re-initiation at a reduced dose if and when the patient recovers.
Use in Special Populations
Elderly
No specific dose adjustment is required for patients aged 65 years and older. However, older patients may experience more frequent oedema, fatigue and laboratory changes, and may benefit from closer monitoring during the first months of treatment.
Hepatic Impairment
No dose adjustment is needed in mild hepatic impairment (Child-Pugh A). In moderate hepatic impairment (Child-Pugh B), a dose reduction may be considered. ROMVIMZA has not been studied in severe hepatic impairment (Child-Pugh C) and is generally not recommended for these patients.
Renal Impairment
No dose adjustment is needed for mild to moderate renal impairment. There is limited information on the use of ROMVIMZA in severe renal impairment or in patients on dialysis; treatment should be managed cautiously by an experienced specialist.
Children and Adolescents
The safety and efficacy of ROMVIMZA in children and adolescents under 18 years of age have not been established. ROMVIMZA is not currently approved or recommended for use in this age group.
Although ROMVIMZA is not formally classified as needing perioperative interruption, you should always inform any surgeon, anaesthetist or dentist that you are taking it. Some specialists choose to pause vimseltinib for several days before and after major surgery, particularly when significant tissue healing is expected.
What Are the Side Effects of ROMVIMZA?
Like all medicines, ROMVIMZA can cause side effects, although not everyone gets them. The pattern of side effects largely reflects the role of CSF1R signalling in normal tissue homeostasis: macrophages help to maintain fluid balance, lipid metabolism, bone turnover and the integrity of certain tissues, so blocking CSF1R can produce predictable, class-related effects. Serious adverse events are uncommon, and most side effects can be managed with conservative measures, dose interruption or dose reduction. Always tell your treatment team about new symptoms, even those that seem minor.
Periorbital and Peripheral Oedema
Swelling around the eyes (periorbital oedema) and in the hands, ankles or feet (peripheral oedema) is the most characteristic side effect of vimseltinib and other CSF1R inhibitors. It typically appears within the first weeks of treatment, is bilateral and symmetrical, and is generally painless. Many patients describe a feeling of puffiness in the eyelids, particularly in the morning, that gradually settles during the day. Most cases are mild to moderate and do not require dose reduction. Useful conservative measures include sleeping with the head slightly elevated, applying cool compresses to the eyelids, gentle compression stockings for the legs, modest sodium restriction in the diet and, in selected cases, a short course of a low-dose diuretic prescribed by your doctor.
Frequency Categories of Reported Side Effects
Very Common
May affect more than 1 in 10 people
- Periorbital oedema (swelling around the eyes)
- Peripheral oedema (swelling of hands, ankles, feet)
- Fatigue / asthenia
- Headache
- Rash, dry skin, pruritus (itching)
- Nausea
- Diarrhoea
- Vomiting
- Constipation
- Muscle pain (myalgia) and joint pain (arthralgia)
- Decreased appetite
- Cough
- Hair colour changes (lightening) or hair texture changes
- Elevated AST and ALT (liver enzymes)
- Elevated alkaline phosphatase
- Elevated total cholesterol and LDL cholesterol
- Elevated triglycerides
- Elevated creatine kinase (CK)
- Decreased neutrophils (mild) and lymphocytes
Common
May affect up to 1 in 10 people
- Generalised oedema (more extensive fluid retention)
- Weight gain
- Dizziness
- Visual disturbance related to periorbital oedema (e.g., blurred vision, dry eye sensation)
- Hypertension or worsening of pre-existing high blood pressure
- Mouth sores (stomatitis)
- Abdominal pain
- Increased bilirubin
- Elevated GGT (gamma-glutamyl transferase)
- Hyperglycaemia (elevated blood sugar)
- Hypoalbuminaemia (low blood albumin)
- Insomnia
Uncommon
May affect up to 1 in 100 people
- Drug-induced liver injury with clinically significant elevations of bilirubin and transaminases
- Severe oedema requiring dose interruption
- Severe skin reactions (extensive rash, widespread eruption)
- Pancreatic enzyme elevation (amylase, lipase)
- QT-interval prolongation on ECG
Rare
May affect up to 1 in 1,000 people
- Severe hypersensitivity reactions including angio-oedema
- Cholestatic liver injury
- Clinically significant cardiac rhythm disturbances
Not Known
Frequency cannot be estimated from available data
- Long-term effects on bone metabolism (CSF1R signalling has a role in osteoclast biology)
- Effects on fertility in humans
- Late-onset effects with prolonged use beyond the duration of clinical trials
Putting Side Effects in Context
In the pivotal MOTION phase 3 trial, ROMVIMZA was generally well tolerated. The most frequently reported treatment-related adverse events were periorbital oedema, fatigue, peripheral oedema and rash. The majority of these events were Grade 1 or 2 (mild or moderate), and discontinuation of treatment because of side effects was infrequent. Importantly, vimseltinib has not been associated with the severe drug-induced cholestatic liver injury seen with some earlier non-selective CSF1R inhibitors, which is attributed to its high selectivity profile and the absence of off-target inhibition of related kinases such as KIT.
Contact your doctor immediately, or seek urgent care, if you develop any of the following: yellowing of the skin or eyes (jaundice), severe or persistent abdominal pain, dark urine, pale stools, severe shortness of breath, sudden swelling of the face or throat with difficulty breathing, widespread painful or blistering rash, or signs of a severe allergic reaction. Do not wait for your next scheduled appointment.
If you experience any side effects, including those not listed here, tell your doctor, pharmacist or nurse. You can also report suspected side effects directly to your national pharmacovigilance authority (for example, the EMA in Europe, the FDA MedWatch programme in the United States or the MHRA Yellow Card Scheme in the United Kingdom). Reporting side effects helps to improve the long-term knowledge of the safety profile of ROMVIMZA.
How Should ROMVIMZA Be Stored?
Keep this medicine out of the sight and reach of children, including the inquisitive hands of grandchildren and visiting children. Do not use ROMVIMZA after the expiry date stated on the bottle and outer carton. The expiry date refers to the last day of that month.
- Temperature: Store at room temperature (typically below 25 °C / 77 °F or as specified on the label). Do not refrigerate or freeze unless your pharmacist explicitly tells you to.
- Original packaging: Keep capsules in the original bottle or blister pack with the desiccant (if supplied), which protects them from moisture.
- Light and humidity: Avoid storing the medicine in bathrooms, near sinks, on radiators or on sunny windowsills.
- Travel: When travelling, carry ROMVIMZA in your hand luggage in its original container together with a copy of your prescription. Do not leave it in a hot car or checked baggage.
- Inspection: Before each dose, check that the capsules look as described in the leaflet. Do not use any capsule that is broken, discoloured or otherwise abnormal.
Do not throw any medicines away via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help to protect the environment and prevent accidental ingestion by children, pets or others.
What Does ROMVIMZA Contain?
Active Substance
The active substance is vimseltinib (international non-proprietary name; development code DCC-3014). Each ROMVIMZA hard capsule contains 14 mg of vimseltinib. Vimseltinib is a small-molecule, switch-control inhibitor of the CSF1R kinase, designed for high target selectivity and a long enough plasma half-life to allow twice-weekly oral dosing.
Inactive Ingredients (Excipients)
The capsule contents typically include conventional pharmaceutical excipients such as a filler (for example, microcrystalline cellulose), a disintegrant, a glidant (for example, colloidal silicon dioxide) and a lubricant (for example, magnesium stearate). The hard capsule shell is usually composed of hypromellose (HPMC) or gelatin, with food-grade colouring agents that vary by strength and country. The exact list of excipients for the capsules sold in your country is provided in the package leaflet supplied with the medicine; refer to it if you have known allergies, are following a vegetarian, vegan or kosher diet, or are sensitive to certain colourings.
Appearance and Packaging
ROMVIMZA 14 mg hard capsules are supplied as opaque capsules of a defined colour combination as described in the package leaflet. They are typically dispensed in plastic bottles fitted with a child-resistant closure and a moisture-absorbing desiccant, or in blister packs. Pack sizes vary depending on the country and prescribing setting.
Marketing Authorisation Holder and Manufacturer
ROMVIMZA was developed and is marketed by Deciphera Pharmaceuticals, now part of the Ono Pharmaceutical group. The product is approved by the U.S. Food and Drug Administration (FDA) and by the European Medicines Agency (EMA), with marketing authorisation in additional countries subject to local regulatory review. Manufacturing and distribution arrangements may differ by region; the local marketing authorisation holder is identified on the carton and in the package leaflet.
Frequently Asked Questions About ROMVIMZA
ROMVIMZA (vimseltinib) is an oral targeted therapy used to treat adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical removal would either cause worsening functional limitation or severe morbidity. TGCT is a rare, locally aggressive but generally non-malignant tumour of the synovial lining of joints, bursae and tendon sheaths. ROMVIMZA selectively inhibits the colony-stimulating factor 1 receptor (CSF1R), the central signalling protein that drives the abnormal macrophage proliferation responsible for the disease.
ROMVIMZA is taken by mouth as a hard capsule. The recommended dose is 30 mg twice weekly, with at least 72 hours between the two weekly doses. Capsules should be swallowed whole with water and may be taken with or without food. Choose the same two days each week to make the schedule easier to remember (for example, every Monday and Thursday). Acid-reducing medicines such as proton pump inhibitors should generally be avoided because they can lower vimseltinib absorption.
Clinical response to ROMVIMZA is generally assessed after approximately 25 weeks of treatment, which is the formal response assessment time point used in the pivotal MOTION phase 3 trial. Many patients report symptom improvements – including reduced pain, less stiffness and improved range of motion – within the first 12 weeks, while measurable tumour shrinkage on MRI is typically observed between weeks 12 and 25. ROMVIMZA is intended for long-term continuous use as long as it is effective and tolerated.
Swelling around the eyes (periorbital oedema) is a class effect of CSF1R inhibitors. CSF1R signalling helps macrophages maintain normal fluid balance and lymphatic drainage in periorbital tissues, which are particularly sensitive because of their loose connective tissue. When CSF1R is blocked, fluid can accumulate locally, producing puffiness that is most noticeable in the morning and gradually settles during the day. The swelling is usually mild, painless and reversible, and rarely requires dose reduction. Cool compresses, sleeping with the head slightly elevated and modest sodium restriction can help.
The most common liver effect of ROMVIMZA is an asymptomatic increase in the liver enzymes AST and ALT, which is typically reversible after dose reduction or temporary interruption. Severe drug-induced liver injury has been uncommon in clinical trials. Vimseltinib was specifically engineered to be highly selective for CSF1R and to avoid the off-target hepatotoxicity that limited some earlier CSF1R inhibitors. Routine liver function monitoring – baseline, every two weeks for the first eight weeks, then monthly to quarterly – allows early detection and management of liver enzyme changes before they cause clinical harm.
ROMVIMZA may reduce the effectiveness of hormonal contraceptives, including combined oral contraceptive pills, progestogen-only pills, hormonal patches, vaginal rings and implants. If you use any of these methods, add a non-hormonal barrier method (such as a male or female condom) or switch to a non-hormonal option such as a copper intrauterine device (IUD). Effective contraception should be continued throughout treatment and for at least one month after the final dose. Discuss the most suitable option for you with your doctor or sexual health clinic.
No. ROMVIMZA is not a traditional cytotoxic chemotherapy. It is a precision targeted therapy that selectively inhibits a single signalling protein (CSF1R) responsible for the abnormal macrophage activity that drives TGCT. As a result, it does not typically cause the classic chemotherapy side effects such as severe bone marrow suppression, hair loss or mucositis, although it has its own profile of adverse events including periorbital oedema, peripheral oedema, hepatic enzyme elevation and skin reactions.
References
- European Medicines Agency (EMA). ROMVIMZA (vimseltinib) – Summary of Product Characteristics. 2025. Available from: EMA Medicines.
- U.S. Food and Drug Administration (FDA). ROMVIMZA (vimseltinib) Prescribing Information. Approved February 2025. Available from: FDA Drug Label.
- Gelderblom H, Bhadri V, Stacchiotti S, et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled phase 3 study. Lancet. 2024;403(10445):2709–2719. doi:10.1016/S0140-6736(24)00875-X.
- Smith BD, Kaufman MD, Wise SC, et al. Vimseltinib: a precision CSF1R inhibitor for tenosynovial giant cell tumor. Mol Cancer Ther. 2021;20(11):2098–2109.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 2.2025.
- Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348–1365 (with subsequent updates).
- Stacchiotti S, Durú-Ojer-Vilumara A, Bauer S, et al. Best practices for the management of tenosynovial giant cell tumor: a position paper. Cancer Treat Rev. 2023;112:102491.
- Tap WD, Wainberg ZA, Anthony SP, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428–437. (Background on CSF1R as a therapeutic target.)
- World Health Organization (WHO). WHO Classification of Tumours of Soft Tissue and Bone. 5th edition. Lyon: IARC Press; 2020.
- British National Formulary (BNF). Vimseltinib monograph. London: Joint Formulary Committee; 2025.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in oncology, sarcoma care, orthopaedic oncology and clinical pharmacology.
Medical Content
iMedic Oncology Editorial Team – specialist physicians in medical oncology and sarcoma management with clinical experience in tenosynovial giant cell tumor
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, NCCN and ESMO guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics and medication safety, including kinase inhibitor therapy
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility for AI and traditional search engines
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.